AMARILLO, Texas, June 15 /PRNewswire/ -- Amarillo Biosciences, Inc.
(OTC Bulletin Board: AMAR) and Hayashibara Biochemical Laboratories (HBL)
announce that the scope of their agreement to develop HBL's natural human
interferon gamma has been broadened to include an inhalation dosage form for
worldwide use (excluding Japan). ABI's interferon gamma will be the sole
natural human interferon gamma under preclinical/clinical development in the
US.
ABI holds the worldwide (excluding Japan) development and distribution
rights for HBL's interferon gamma when used for low dose oral administration.
HBL's natural human interferon gamma is approved for use in Japan in
injectable form for the treatment of mycosis fungoides. In the United States,
an injectable recombinant interferon gamma is approved for the treatment of
chronic granulomatous disease and osteopetrosis. Interferon gamma is also
under study for several other serious, potentially fatal diseases.
Dr. Joseph Cummins, President & CEO of ABI, stated, "Our goal is to
develop low dose oral and inhalation dosage forms of natural human interferon
gamma that will provide therapeutic benefits with improved convenience and a
much better side effect profile than the currently available injectable
product. Moreover, we are very pleased to be able to continue our interferon
gamma development work with Dr. Ed Amento and the Molecular Medicine Research
Institute (MMRI), which uses the most recent advances in cellular and
molecular biology, immunology and medicinal chemistry to enhance the
understanding of human disease."
Amarillo Biosciences, founded in 1984, is a pioneer in researching the use
of low dose orally-administered natural human interferons as treatments for a
variety of conditions including Sjogren's syndrome, fibromyalgia syndrome,
Behcet's disease, hepatitis B and C, and opportunistic infections in patients
who are HIV positive. ABI is conducting a Phase III clinical program in
Sjogren's syndrome in the United States.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the company's other product
candidates and other risks detailed from time to time in the company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Description of Business" of the company's Form 10-KSB for the year ended
Dec. 31, 1999.
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html or fax,
800-758-5804, ext. 118055
CONTACT:
Dr. Joseph M. Cummins, Chief Executive
Officer, 806-376-1741, #13, or email, jcummins@amarbio.com, or
Philip C. Fox, D.D.S., Director of Research & Development,
301-320-8200, or email, pcfox@amarbio.com, both of Amarillo
Biosciences, Inc.
|
